- Home
- PHAT vs ACDC Comparison
PHAT vs ACDC Comparison
Compare PHAT & ACDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | ACDC |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 971.3M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PHAT | ACDC |
|---|---|---|
| Price | $10.67 | $6.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $19.50 | $5.33 |
| AVG Volume (30 Days) | 940.4K | ★ 1.6M |
| Earning Date | 04-30-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $175,110,000.00 | ★ $1,941,800,000.00 |
| Revenue This Year | $92.15 | N/A |
| Revenue Next Year | $59.79 | $6.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $3.08 |
| 52 Week High | $18.31 | $10.70 |
Technical Indicators
Market Signals| Indicator | PHAT | ACDC |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 59.14 |
| Support Level | $10.06 | $3.48 |
| Resistance Level | $12.62 | $7.47 |
| Average True Range (ATR) | 0.67 | 0.54 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 35.00 | 50.28 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About ACDC ProFrac Holding Corp.
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.